Glucocorticoid receptor mutants: Man-made tools for functional research

Trends in Endocrinology and Metabolism

Volumn 22, Issue 8, 2011, Pages 295-310

  Beck, Ilse M ^a   De Bosscher, Karolien ^a   Haegeman, Guy ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; GLUCOCORTICOID RECEPTOR;

GENE CONTROL; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; LIGAND BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; REVIEW; TRANSACTIVATION; TRANSCRIPTION REGULATION;

ANIMALS; HUMANS; MUTATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, GLUCOCORTICOID;

EID: 79960912981     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.03.009     Document Type: Review

References (106)

1. Schäcke H., et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:227-232.
2. McDonough A.K., et al. The epidemiology of glucocorticoid-associated adverse events. Curr. Opin. Rheumatol. 2008, 20:131-137.
3. Hollenberg S.M., et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985, 318:635-641.
4. Nicolaides N.C., et al. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010, 75:1-12.
5. Beck I.M., et al. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr. Rev. 2009, 30:830-882.
6. Kassel O., Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell. Endocrinol. 2007, 275:13-29.
7. Rosenfeld M.G., et al. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
8. Gross K.L., Cidlowski J.A. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol. Metab. 2008, 19:331-339.
9. Danielsen M., et al. Mutational analysis of the mouse glucocorticoid receptor. Cancer Res. 1989, 49:2286s-2291s.
10. Yudt M.R., Cidlowski J.A. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Mol. Endocrinol. 2001, 15:1093-1103.
11. Garabedian M.J., Yamamoto K.R. Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. Mol. Biol. Cell. 1992, 3:1245-1257.
12. Tao Y.G., et al. Mutations of glucocorticoid receptor differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and efficacy of gene induction and repression. Biochemistry 2008, 47:7648-7662.
13. Sheldon L.A., et al. A ligand binding domain mutation in the mouse glucocorticoid receptor functionally links chromatin remodeling and transcription initiation. Mol. Cell. Biol. 1999, 19:8146-8157.
14. Zhang S., et al. Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Mol. Endocrinol. 1996, 10:24-34.
15. Zhang J., et al. A critical role of helix 3-helix 5 interaction in steroid hormone receptor function. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2707-2712.
16. Zhang J., et al. Characterization of a novel gain of function glucocorticoid receptor knock-in mouse. J. Biol. Chem. 2009, 284:6249-6259.
17. Bledsoe R.K., et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002, 110:93-105.
18. Matthews L., et al. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 2009, 150:75-86.
19. De Bosscher K., et al. Classic glucocorticoids versus non-steroidal glucocorticoid receptor modulators: survival of the fittest regulator of the immune system?. Brain Behav. Immun. 2010, 24:1035-1042.
20. De Bosscher K., et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15827-15832.
21. Maru B.S., et al. Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone 2009, 44:102-112.
22. Savory J.G., et al. Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid receptor. Mol. Cell. Biol. 1999, 19:1025-1037.
23. Haché R.J., et al. Nucleocytoplasmic trafficking of steroid-free glucocorticoid receptor. J. Biol. Chem. 1999, 274:1432-1439.
24. Carrigan A., et al. An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation. J. Biol. Chem. 2007, 282:10963-10971.
25. Schaaf M.J., et al. Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility. Mol. Endocrinol. 2005, 19:1501-1515.
26. Picard D., Yamamoto K.R. Two signals mediate hormone-dependent nuclear localization of the glucocorticoid receptor. EMBO J. 1987, 6:3333-3340.
27. Freedman N.D., Yamamoto K.R. Importin 7 and importin alpha/importin beta are nuclear import receptors for the glucocorticoid receptor. Mol. Biol. Cell. 2004, 15:2276-2286.
28. Tao T., et al. Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2006, 35:668-680.
29. Echeverria P.C., et al. Nuclear import of the glucocorticoid receptor-hsp90 complex through the nuclear pore complex is mediated by its interaction with Nup62 and importin beta. Mol. Cell. Biol. 2009, 29:4788-4797.
30. Beck I.M., et al. Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibition. EMBO J. 2008, 27:1682-1693.
31. Lombardi M., et al. Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J. Cell Biol. 2008, 182:327-340.
32. Amazit L., et al. Subcellular localization and mechanisms of nucleocytoplasmic trafficking of steroid receptor coactivator-1. J. Biol. Chem. 2003, 278:32195-32203.
33. Kino T., et al. Protein 14-3-3sigma interacts with and favors cytoplasmic subcellular localization of the glucocorticoid receptor, acting as a negative regulator of the glucocorticoid signaling pathway. J. Biol. Chem. 2003, 278:25651-25656.
34. Kumar S., et al. Shuttling components of nuclear import machinery involved in nuclear translocation of steroid receptors exit nucleus via exportin-1/CRM-1 independent pathway. Biochim. Biophys. Acta 2004, 1691:73-77.
35. Holaska J.M., et al. Ca2+-dependent nuclear export mediated by calreticulin. Mol. Cell. Biol. 2002, 22:6286-6297.
36. Walther R.F., et al. Nuclear export of the glucocorticoid receptor is accelerated by cell fusion-dependent release of calreticulin. J. Biol. Chem. 2003, 278:37858-37864.
37. Liu J., DeFranco D.B. Protracted nuclear export of glucocorticoid receptor limits its turnover and does not require the exportin 1/CRM1-directed nuclear export pathway. Mol. Endocrinol. 2000, 14:40-51.
38. Giannoukos G., et al. The seven amino acids (547-553) of rat glucocorticoid receptor required for steroid and hsp90 binding contain a functionally independent LXXLL motif that is critical for steroid binding. J. Biol. Chem. 1999, 274:36527-36536.
39. Kaul S., et al. Mutations at positions 547-553 of rat glucocorticoid receptors reveal that hsp90 binding requires the presence, but not defined composition, of a seven-amino acid sequence at the amino terminus of the ligand binding domain. J. Biol. Chem. 2002, 277:36223-36232.
40. Dong D.D., et al. Functional analysis of the LXXLL motifs of the human glucocorticoid receptor: association with altered ligand affinity. J. Steroid Biochem. Mol. Biol. 2006, 101:106-117.
41. Rogatsky I., et al. Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13845-13850.
42. Danielian P.S., et al. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 1992, 11:1025-1033.
43. Kucera T., et al. A point mutation of the AF2 transactivation domain of the glucocorticoid receptor disrupts its interaction with steroid receptor coactivator 1. J. Biol. Chem. 2002, 277:26098-26102.
44. Alroy I., Freedman L.P. DNA binding analysis of glucocorticoid receptor specificity mutants. Nucleic Acids Res. 1992, 20:1045-1052.
45. Schena M., et al. Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities. Genes Dev. 1989, 3:1590-1601.
46. Reichardt H.M., et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998, 93:531-541.
47. Reichardt H.M., et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001, 20:7168-7173.
48. Lidén J., et al. A new function for the C-terminal zinc finger of the glucocorticoid receptor Repression of RelA transactivation. J. Biol. Chem. 1997, 272:21467-21472.
49. Nissen R.M., Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000, 14:2314-2329.
50. Ray A., et al. Repressor to activator switch by mutations in the first Zn finger of the glucocorticoid receptor: is direct DNA binding necessary?. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:7086-7090.
51. Li G., et al. Role of steroid receptor coactivators in glucocorticoid and transforming growth factor beta regulation of plasminogen activator inhibitor gene expression. Mol. Endocrinol. 2006, 20:1025-1034.
52. Heck S., et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994, 13:4087-4095.
53. Kassel O., et al. A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters. Genes Dev. 2004, 18:2518-2528.
54. Doucas V., et al. Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11893-11898.
55. Diefenbacher M., et al. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol. Endocrinol. 2008, 22:1767-1780.
56. Diefenbacher M.E., et al. The nuclear isoform of the LIM domain protein Trip6 integrates activating and repressing signals at the promoter-bound glucocorticoid receptor. Mol. Cell. Endocrinol. 2010, 320:58-66.
57. Wu J., et al. Repression of p65 transcriptional activation by the glucocorticoid receptor in the absence of receptor-coactivator interactions. Mol. Endocrinol. 2004, 18:53-62.
58. Arancibia S., et al. Phosphatidylinositol 3-kinase interacts with the glucocorticoid receptor upon TLR2 activation. J. Cell. Mol. Med. 2011, 15:339-349.
59. McKay L.I., Cidlowski J.A. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol. Endocrinol. 1998, 12:45-56.
60. Bladh L.G., et al. Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-kappaB and activator protein-1 repression. Mol. Pharmacol. 2005, 67:815-826.
61. Tao Y., et al. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J. Biol. Chem. 2001, 276:2329-2332.
62. Meyer T., et al. The rat glucocorticoid receptor mutant K461A differentiates between two different mechanisms of transrepression. J. Biol. Chem. 1997, 272:21090-21095.
63. Sharma S., Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood 2008, 112:1338-1345.
64. Rauch A., et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 2010, 11:517-531.
65. Donet E., et al. Transrepression function of the glucocorticoid receptor regulates eyelid development and keratinocyte proliferation but is not sufficient to prevent skin chronic inflammation. Mol. Endocrinol. 2008, 22:799-812.
66. Bayo P., et al. Glucocorticoid receptor is required for skin barrier competence. Endocrinology 2008, 149:1377-1388.
67. Wang Z., et al. Modulation of glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-associated protein phosphatase. Mol. Endocrinol. 2007, 21:625-634.
68. Galliher-Beckley A.J., Cidlowski J.A. Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 2009, 61:979-986.
69. Dephoure N., et al. A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10762-10767.
70. Krstic M.D., et al. Mitogen-activated and cyclin-dependent protein kinases selectively and differentially modulate transcriptional enhancement by the glucocorticoid receptor. Mol. Cell. Biol. 1997, 17:3947-3954.
71. Wang Z., Garabedian M.J. Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27Kip1. J. Biol. Chem. 2003, 278:50897-50901.
72. Kino T., et al. Cyclin-dependent kinase 5 differentially regulates the transcriptional activity of the glucocorticoid receptor through phosphorylation: clinical implications for the nervous system response to glucocorticoids and stress. Mol. Endocrinol. 2007, 21:1552-1568.
73. Webster J.C., et al. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J. Biol. Chem. 1997, 272:9287-9293.
74. Blind R.D., Garabedian M.J. Differential recruitment of glucocorticoid receptor phospho-isoforms to glucocorticoid-induced genes. J. Steroid Biochem. Mol. Biol. 2008, 109:150-157.
75. Miller A.L., et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol. Endocrinol. 2005, 19:1569-1583.
76. Chen W., et al. Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol. Endocrinol. 2008, 22:1754-1766.
77. Avenant C., et al. Glucocorticoid receptor phosphorylation modulates transcription efficacy through GRIP-1 recruitment. Biochemistry 2010, 49:972-985.
78. Nader N., et al. AMPK regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 MAPK. Mol. Endocrinol. 2010, 24:1748-1764.
79. Garza A.M., et al. Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Mol. Cell. Biol. 2010, 30:220-230.
80. Rogatsky I., et al. Antagonism of glucocorticoid receptor transcriptional activation by the c-Jun N-terminal kinase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:2050-2055.
81. Itoh M., et al. Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol. Endocrinol. 2002, 16:2382-2392.
82. Galliher-Beckley A.J., et al. Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol. Cell. Biol. 2008, 28:7309-7322.
83. Rogatsky I., et al. Phosphorylation and inhibition of rat glucocorticoid receptor transcriptional activation by glycogen synthase kinase-3 (GSK-3) Species-specific differences between human and rat glucocorticoid receptor signaling as revealed through GSK-3 phosphorylation. J. Biol. Chem. 1998, 273:14315-14321.
84. Ismaili N., et al. Stabilization of the unliganded glucocorticoid receptor by TSG101. J. Biol. Chem. 2005, 280:11120-11126.
85. Holmstrom S.R., et al. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX. Mol. Endocrinol. 2008, 22:2061-2075.
86. Tian S., et al. Small ubiquitin-related modifier-1 (SUMO-1) modification of the glucocorticoid receptor. Biochem. J. 2002, 367:907-911.
87. Davies L., et al. Cross talk of signaling pathways in the regulation of the glucocorticoid receptor function. Mol. Endocrinol. 2008, 22:1331-1344.
88. Wallace A.D., Cidlowski J.A. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 2001, 276:42714-42721.
89. Wallace A.D., et al. Lysine 419 targets human glucocorticoid receptor for proteasomal degradation. Steroids 2010, 75:1016-1023.
90. Deroo B.J., et al. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol. Cell. Biol. 2002, 22:4113-4123.
91. Ito K., et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 2006, 203:7-13.
92. Nader N., et al. Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications. FASEB J. 2009, 23:1572-1583.
93. Daniel A.R., et al. The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol. Endocrinol. 2010, 24:2126-2138.
94. Fu M., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 2000, 275:20853-20860.
95. Wang C., et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 2001, 276:18375-18383.
96. Milhon J., et al. Identification of amino acids in the tau 2-region of the mouse glucocorticoid receptor that contribute to hormone binding and transcriptional activation. Mol. Endocrinol. 1997, 11:1795-1805.
97. Avenant C., et al. Role of ligand-dependent GR phosphorylation and half-life in determination of ligand-specific transcriptional activity. Mol. Cell. Endocrinol. 2010, 327:72-88.
98. Starr D.B., et al. Intracellular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev. 1996, 10:1271-1283.
99. Necela B.M., Cidlowski J.A. A single amino acid change in the first zinc finger of the DNA binding domain of the glucocorticoid receptor regulates differential promoter selectivity. J. Biol. Chem. 2004, 279:39279-39288.
100. Adams M., et al. Homodimerization of the glucocorticoid receptor is not essential for response element binding: activation of the phenylethanolamine N-methyltransferase gene by dimerization-defective mutants. Mol. Endocrinol. 2003, 17:2583-2592.
101. Ricketson D., et al. A conformational switch in the ligand-binding domain regulates the dependence of the glucocorticoid receptor on Hsp90. J. Mol. Biol. 2007, 368:729-741.
102. Hollenberg S.M., et al. Identification of two regions of the human glucocorticoid receptor hormone binding domain that block activation. Cancer Res. 1989, 49:2292s-2294s.
103. Housley P.R., et al. Evidence that the conserved region in the steroid binding domain of the glucocorticoid receptor is required for both optimal binding of hsp90 and protection from proteolytic cleavage A two-site model for hsp90 binding to the steroid binding domain. J. Biol. Chem. 1990, 265:12778-12781.
104. Lemke U., et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008, 8:212-223.
105. Lang P.A., et al. PI3 kinase dependent stimulation of gastric acid secretion by dexamethasone. Cell. Physiol. Biochem. 2007, 20:527-534.
106. Sandu C., et al. Role of the serum and glucocorticoid inducible kinase SGK1 in glucocorticoid stimulation of gastric acid secretion. Pflugers Arch. 2007, 455:493-503.